Role of Serum Levels of Thymidine Kinase 1 in Diagnosis and Differentiating of Prostatic Tumor

Abstract

Background: Both benign prostatic (BPH) and prostate (Pca) hyperplasia include prostate enlargement. The
distinction between benign prostatic hyperplasia and prostate cancer is a major challenge, since the prostatic
specific antigen (PSA) cannot be considered a reliable predictor of prostate cancer. Aims: Efficiency of
serum thymidine kinase 1 and PSA-related biomarkers in prostate tumor, BPH and PCa diagnosis and
differentiation, especially when serum PSA is in the gray (4-10 ng/ml) region and in the pronostic of these
patients after surgical therapy. Subjects and Methods: A case control and cross-sectional review. There
were 110 elderly patients (45-81 years) and 45 controle. Serum experiments involved the use of ELISA
technologies to measure tPSA, fPSA, and TK1. Result: In comparison to both of the BPH and controls, the
mean (±S D) of serum tPSA and fPSA in Pca were significantly improved (all p =0,001) while the mean
value of f PCa in comparison with BPH and control was dramatically decreased (p = 0,001) for fPSA/tPSA.
There was no difference between BPH and controls in these parameters. In both of the Pca and Controls
(P<0.001) the mean TC1 was slightly higher (P<0.001). This serum TK1 has the most receptive and specific
diagnostic and differentiating potency in the gray zone of tPSA (4-10 ng/ml), which has tPSA in the gray
zone with AUC=1 in the 924 pg/ml cut-off zone.
Conclusion: Serum level of TK1 was superior of tPSA in diagnosis of prostate tumor and differentiating
between BPH and PCa.